睿知中国医院研究地图
候选清单

杭州中国科学院大学

浙江省肿瘤医院

Zhejiang Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 16 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

浙江省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma19 篇牵头论文牵头 6 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma50 篇牵头论文牵头 6 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma35 篇牵头论文牵头 3 项开放试验
  4. 胃癌Stomach cancer106 篇牵头论文牵头 11 项开放试验
  5. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma2 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma2 篇牵头论文
  10. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  11. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  12. 范可尼贫血Fanconi anaemia2 篇牵头论文
  13. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  14. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  15. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  16. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:视网膜母细胞瘤、脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.8%。

牵头论文
19
2021–2025 年
牵头试验
26
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 0020232024: 6620242025: 882025

杭州有 8 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 17

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Metastatic Nasopharyngeal Carcinoma
    分期
    I期
    开始
    2023-07
    登记号
    NCT06886347

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  2. 正在招募
    Radiotherapy Combined With Endostatin and Capecitabine for NPC
    分期
    II期
    开始
    2022-08
    登记号
    NCT05514275

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:浙江省肿瘤医院;另有 2 家列出的医院为研究中心宁波、杭州

  3. 正在招募
    SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
    分期
    II期
    开始
    2022-09
    登记号
    NCT05652192

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  4. 正在招募
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2021-11
    登记号
    NCT05126160

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:浙江省肿瘤医院;另有 4 家列出的医院为研究中心宁波、杭州、武汉、温州

  5. 即将招募
    Platinum-Free Regimen in Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2026-09
    登记号
    NCT07794488

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  6. 即将招募
    Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
    分期
    II期
    开始
    2024-12
    登记号
    NCT06752382

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  7. 正在招募
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    分期
    III期
    开始
    2026-04
    登记号
    NCT07235319

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 4 家列出的医院为研究中心南宁、广州、杭州、福州、长沙

  8. 正在招募
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    分期
    II期
    开始
    2025-04
    登记号
    NCT06839066

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙

  9. 正在招募
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    分期
    I/II期
    开始
    2025-11
    登记号
    NCT07258979

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关

  10. 正在招募
    鼻咽癌个体化颈部预防性照射试验Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    分期
    III期
    开始
    2025-09
    登记号
    NCT07303023

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、成都、杭州、重庆

  11. 正在招募
    喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    分期
    III期
    开始
    2025-12
    登记号
    NCT07311772

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  12. 正在招募
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328854

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  13. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

  14. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

  15. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

  16. 正在招募
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    分期
    III期
    开始
    2022-04
    登记号
    NCT05340491

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  17. 正在招募
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    分期
    III期
    开始
    2020-03
    登记号
    NCT03907826

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题放疗技术影像与人工智能复发与转移
论文中的科室放疗科耳鼻喉/头颈外科病理/检验科影像/核医学科
牵头的论文19
  1. Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial.2025British journal of hospital medicine (London, England : 2005)RCT
  2. Advances in Nasopharyngeal Carcinoma Staging: from the 7th to the 9th Edition of the TNM System and Future Outlook.2025Current oncology reports
  3. Evaluating the reduction of elective radiotherapy fields for de novo metastatic nasopharyngeal carcinoma in the immunotherapy era.2025Head & neck
  4. Mecapegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study.2025Head & neck免费全文
  5. Effect of Dendrobium Officinale on Radioactive Oral Mucositis of Nasopharyngeal Carcinoma and Changes of Oral Microecology.2025Integrative cancer therapiesRCT免费全文
  6. Concurrent chemotherapy for older patients with locoregionally advanced nasopharyngeal carcinoma: A randomized clinical trial.2025Journal of geriatric oncologyRCT
  7. Effects of Antibiotics on First-line Immunotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  8. Nasopharyngeal Giant Carcinoma Mimicking Intracranial Lesions: A Case Report and Literature Review.2025The American journal of case reports免费全文
  9. Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma.2024Cancer science免费全文
  10. Use of 18F-FDG PET/MRI as an Initial Staging Procedure for Nasopharyngeal Carcinoma.2024Journal of magnetic resonance imaging : JMRI
  11. Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.2024Oral oncology
  12. Predictive value of delta radiomics in xerostomia after chemoradiotherapy in patients with stage III-IV nasopharyngeal carcinoma.2024Radiation oncology (London, England)免费全文
  13. Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.2024Signal transduction and targeted therapy免费全文
  15. Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma.2022BMC cancer免费全文
  16. Detection and staging of recurrent or metastatic nasopharyngeal carcinoma in the era of FDG PET/MR.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  17. Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study.2022Radiation oncology (London, England)免费全文
  18. SP1-induced AFAP1-AS1 contributes to proliferation and invasion by regulating miR-497-5p/CELF1 pathway in nasopharyngeal carcinoma.2021Human cell
  19. The Usefulness of Pretreatment MR-Based Radiomics on Early Response of Neoadjuvant Chemotherapy in Patients With Locally Advanced Nasopharyngeal Carcinoma.2021Oncology research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)50
  1. Platinum-Free Regimen in Nasopharyngeal Carcinoma即将招募NCT07794488牵头方II期2026-09 启动
  2. Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC即将招募NCT06752382牵头方II期2024-12 启动
  3. Radiotherapy Combined With Endostatin and Capecitabine for NPC正在招募NCT05514275牵头方II期2022-08 启动
  4. SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC正在招募NCT05652192牵头方II期2022-09 启动
  5. Immune Score Based Radiomics in Nasopharyngeal Carcinoma正在招募NCT05126160牵头方2021-11 启动
  6. Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma进行中,不再招募NCT06055816牵头方II期2023-10 启动
  7. Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma进行中,不再招募NCT05813626牵头方II期2023-04 启动
  8. Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma状态不明NCT05232552牵头方II期2021-01 启动
  9. Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis状态不明NCT03904225牵头方II期2018-12 启动
  10. Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis状态不明NCT03720340牵头方III期2018-10 启动
  11. Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients状态不明NCT03411954牵头方2018-01 启动
  12. PET/MR in Locally Advanced Nasopharyngeal Carcinoma状态不明NCT03657017牵头方不分期2018-06 启动
  13. TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients状态不明NCT03588403牵头方2018-07 启动
  14. Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions状态不明NCT03129412牵头方II期2017-04 启动
  15. Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma已完成NCT03025958牵头方II期2017-03 启动
  16. Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)状态不明NCT03213587牵头方II期2017-07 启动
  17. Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT03058432牵头方II期2017-01 启动
  18. A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients状态不明NCT02948699牵头方IV期2016-11 启动
  19. A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.状态不明NCT02878889牵头方II期2016-08 启动
  20. Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma状态不明NCT03015727牵头方III期2016-12 启动
  21. Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma状态不明NCT02945878牵头方2016-10 启动
  22. Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy状态不明NCT03647527牵头方2016-09 启动
  23. Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT01915134牵头方III期2013-08 启动
  24. Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma状态不明NCT01536223牵头方III期2012-04 启动
  25. Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma状态不明NCT01612286牵头方II期2012-05 启动
  26. Metastatic Nasopharyngeal Carcinoma正在招募NCT06886347牵头方(推断)I期2023-07 启动
  27. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC正在招募NCT07235319研究中心III期2026-04 启动
  28. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid正在招募NCT07311772研究中心III期2025-12 启动
  29. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  30. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma正在招募NCT07328854研究中心III期2025-11 启动
  31. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC正在招募NCT07303023研究中心III期2025-09 启动
  32. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy正在招募NCT06839066研究中心II期2025-04 启动
  33. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  34. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  35. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy正在招募NCT05892354研究中心不分期2023-06 启动
  36. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial正在招募NCT05340491研究中心III期2022-04 启动
  37. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients正在招募NCT03907826研究中心III期2020-03 启动
  38. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  39. Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma进行中,不再招募NCT05780372研究中心III期2023-08 启动
  40. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma进行中,不再招募NCT04907370研究中心III期2021-08 启动
  41. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  42. A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma已完成NCT04736810研究中心II期2021-02 启动
  43. Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma已完成NCT03984357研究中心II期2020-03 启动
  44. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors已完成NCT04215978研究中心I期2020-01 启动
  45. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
  46. A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients状态不明NCT04061278研究中心III期2019-08 启动
  47. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  48. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma状态不明NCT02633176研究中心III期2015-01 启动
  49. The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma已完成NCT01187238研究中心II期2010-05 启动
  50. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)35
  1. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncology论文
  2. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncology论文
  3. A prospective randomized controlled study about oral nutrition supplement in local advanced nasopharyngeal carcinoma patients: An update of long-term survival.2025Journal of Clinical Oncology论文
  4. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  5. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncology论文
  6. Efficacy and safety of PD-1/PD-L1 inhibitors for relapsed/metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis2025Letters in Drug Design & Discovery综述
  7. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncology会议摘要
  8. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  9. Real-word research on the effect and safety of gemcitabine combined with PD-1 inhibitors and recombinant human endostatin in refractory recurrent nasopharyngeal carcinoma.2025Journal of Clinical Oncology论文
  10. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  11. 1498 Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial2024Journal for ImmunoTherapy of Cancer会议摘要
  12. 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial2024Annals of Oncology论文
  13. 890P Stereotactic body radiation therapy combined with chemotherapy and tislelizumab in metastatic nasopharyngeal carcinoma: A prospective, single-arm, phase II study2024Annals of Oncology论文
  14. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncology会议摘要
  15. Development of the Ninth Version of the Nasopharyngeal Cancer TNM Staging System by the American Joint Committee on Cancer and Union for International Cancer Control (AJCC/UICC): Recommendations Based on a Multicenter Validation Study and C2024SSRN Electronic Journal预印本
  16. Induction chemotherapy with nab-paclitaxel plus nedaplatin plus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective real-world study.2024Journal of Clinical Oncology会议摘要
  17. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.2024Journal of Clinical Oncology会议摘要
  18. Maxillary sinus anterior wall recurrence after intensity-modulated radiotherapy for nasopharyngeal carcinoma2024International Journal of Radiation Research论文
  19. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  20. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncology会议摘要
  21. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  22. Real-world effectiveness and safety of PD-1 inhibitors combined with recombinant human endostatin and chemotherapy in refractory, recurrent/metastatic nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  23. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.2024Journal of Clinical Oncology会议摘要
  24. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  25. CSF-1R as a metastasis-related gene in nasopharyngeal carcinoma: A bioinformatics screening and immunohistochemistry verification2023Research Square预印本
  26. Investigating transfer learning to improve the deep-learning-based segmentation of organs at risk among different medical centers for nasopharyngeal carcinoma2023Frontiers in Physics论文
  27. Quality of life and Its Association With Radiation-Induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma During Radiotherapy: A Prospective Study2023Research Square预印本
  28. A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).2022Journal of Clinical Oncology会议摘要
  29. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.2022Journal of Clinical Oncology会议摘要
  30. Development and Validation of a Pre-Treatment Magnetic Resonance Imaging Radiomics-Based Signature to Predict Progression-Free Survival in Patients with Locally Advanced Nasopharyngeal Carcinoma2022SSRN Electronic Journal预印本
  31. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  32. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.2022Journal of Clinical Oncology会议摘要
  33. UNC119 promotes the malignant progression of nasopharyngeal carcinoma cells by regulating Wnt/β-catenin pathway2022ScienceAsia论文
  34. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancer会议摘要
  35. A phase III multicenter randomized clinical trial to compare cisplatin plus fluorouracil with or without docetaxel as the first-line induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Long-term outcomes update.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 50 篇,占 1.7%。

牵头论文
50
2021–2025 年
牵头试验
16
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 9920222023: 9920232024: 161620242025: 992025

杭州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
    分期
    II期
    开始
    2024-03
    登记号
    NCT06272214

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  2. 正在招募
    Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-06
    登记号
    NCT06413342

    年龄 70 岁 至 85 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  3. 正在招募
    Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)
    分期
    II期
    开始
    2024-08
    登记号
    NCT06509568

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  4. 正在招募
    A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
    分期
    II期
    开始
    2023-10
    登记号
    NCT06190639

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江省肿瘤医院杭州

  5. 正在招募
    Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
    分期
    II期
    开始
    2022-08
    登记号
    NCT05507411

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院;另有 2 家列出的医院为研究中心宁波、杭州

  6. 邀请入组
    Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
    分期
    I/II期
    开始
    2022-06
    登记号
    NCT06303583

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  7. 正在招募
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    分期
    I/II期
    开始
    2026-03
    登记号
    NCT07405151

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、厦门、合肥、徐州、杭州、济南、郑州

  8. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  9. 正在招募
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    分期
    II期
    开始
    2024-10
    登记号
    NCT06637163

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 4 家列出的医院为研究中心上海、天津、杭州、汕头、沈阳

  10. 正在招募
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    分期
    I/II期
    开始
    2023-05
    登记号
    NCT05319730

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、厦门、合肥、新乡、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗分子标志物与基因免疫治疗
论文中的科室放疗科肿瘤内科病理/检验科消化/肝病科
牵头的论文50
  1. CircMMP11 is a Potential Recurrence Biomarker and Facilitates Progression of Esophageal Squamous Cell Carcinoma.2026Biochemical genetics
  2. Single-cell profiling identifies biomarkers for immunochemotherapy in esophageal squamous cell carcinoma.2025Cancer letters
  3. Neoadjuvant Chemo (radio) therapy and anastomotic leakage risk in patients with esophageal squamous cell carcinoma.2025Cirugia y cirujanos
  4. Recurrence patterns following neoadjuvant chemotherapy combined with immunotherapy for esophageal squamous cell carcinoma.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  5. Serum creatinine to cystatin C ratio is a prognostic indicator in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.2025Frontiers in immunology免费全文
  6. Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.2025Frontiers in immunology免费全文
  7. The systemic oxidative stress index predicts clinical outcomes of esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.2025Frontiers in immunology免费全文
  8. Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.2025Journal for immunotherapy of cancer免费全文
  9. Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy.2025Journal for immunotherapy of cancer免费全文
  10. Outcomes of neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.2025Surgery
  11. ASO Author Reflections: A Novel, Sensitive, and Effective Index in Predicting Therapeutic Response of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  12. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  13. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.2024Biomolecules & biomedicine免费全文
  14. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  15. Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study.2024Frontiers in immunology免费全文
  16. Association of the Scottish inflammatory prognostic score with treatment-related adverse events and prognosis in esophageal cancer receiving neoadjuvant immunochemotherapy.2024Frontiers in immunology免费全文
  17. Correlation of NAT10 expression with clinical data and survival profiles in esophageal squamous cell carcinoma patients, and its impact on cell proliferation and apoptosis.2024Histology and histopathology
  18. Bioinformatics Analysis Reveals a Novel Prognostic Model for Esophageal Squamous Cell Carcinoma.2024International journal of medical sciences免费全文
  19. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.2024Journal for immunotherapy of cancer免费全文
  20. Plasma-based lipidomics reveals potential diagnostic biomarkers for esophageal squamous cell carcinoma: a retrospective study.2024PeerJ免费全文
  21. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.2024PloS one免费全文
  22. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  23. Preoperative inflammatory burden index for prognostication in esophageal squamous cell carcinoma undergoing radical resection.2024Scientific reports免费全文
  24. Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.2024Scientific reports免费全文
  25. Clinical significance of preoperative CALLY index for prognostication in patients with esophageal squamous cell carcinoma undergoing surgery.2024Scientific reports免费全文
  26. D-dimer levels predict the treatment efficacy and prognosis of esophageal squamous cell carcinoma treated with PD-1/PD-L1 inhibitors.2024The International journal of biological markers
  27. Preoperative serum bilirubin is an independent prognostic factor for curatively resected esophageal squamous cell carcinoma.2023BMC cancer免费全文
  28. Clinical and prognostic significance of perioperative change in red cell distribution width in patients with esophageal squamous cell carcinoma.2023BMC cancer免费全文
  29. Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study.2023Biomolecules & biomedicine免费全文
  30. Using clinical and radiomic feature-based machine learning models to predict pathological complete response in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation.2023European radiology
  31. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.2023Frontiers in immunology免费全文
  32. Clinical utility of preoperative pan-immune-inflammation value (PIV) for prognostication in patients with esophageal squamous cell carcinoma.2023International immunopharmacology
  33. Comprehensive nutritional index predicts clinical outcomes for esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.2023International immunopharmacology
  34. Genomic and Transcriptomic Remodeling by Neoadjuvant Chemoradiotherapy (nCRT) and the Indicative Role of Acquired INDEL Percentage for nCRT Efficacy in Esophageal Squamous Cell Carcinoma.2023International journal of radiation oncology, biology, physics
  35. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.2023Nature medicine免费全文
  36. ASO Author Reflection: The TME-Related Gene AIF1 Signature Predicts Esophageal Carcinoma Prognosis.2022Annals of surgical oncology
  37. The Novel Tumor Microenvironment-Related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer.2022Annals of surgical oncology
  38. Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma.2022BMC cancer免费全文
  39. Development and validation of a novel pre-operative comprehensive prognostic score in esophageal squamous cell carcinoma.2022Bosnian journal of basic medical sciencesRCT免费全文
  40. Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.2022Cancer control : journal of the Moffitt Cancer CenterRCT免费全文
  41. A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma.2022Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  42. The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study.2022Frontiers in immunology免费全文
  43. Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma.2022Journal of immunology research免费全文
  44. Nucleic acid aptamer controls mycoplasma infection for inhibiting the malignancy of esophageal squamous cell carcinoma.2022Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  45. LETM1 (leucine zipper-EF-hand-containing transmembrane protein 1) silence reduces the proliferation, invasion, migration and angiogenesis in esophageal squamous cell carcinoma via KIF14 (kinesin family member 14).2021Bioengineered免费全文
  46. The preoperative hemoglobin, albumin, lymphocyte and platelet (HALP) score is a useful predictor in patients with resectable esophageal squamous cell carcinoma.2021Bosnian journal of basic medical sciences免费全文
  47. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.2021Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  48. WISP3 suppresses ESCC progression by inhibiting the IGF-2-IGF1R-AKT signaling cascade.2021Experimental cell research
  49. Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma.2021Journal of pharmaceutical and biomedical analysis
  50. Retrospective analysis of predictive factors for lymph node metastasis in superficial esophageal squamous cell carcinoma.2021Scientific reports免费全文
中文论文(未计入)2
  1. [Research progress on the regulation of ferroptosis by non-coding RNAs in esophageal squamous cell cancer].2025Sheng li xue bao : [Acta physiologica Sinica]
  2. [Neoadjuvant chemoradiotherapy versus neoadjuvant chemo-immunotherapy for locally advanced esophageal squamous cell carcinoma].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)34
  1. Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma正在招募NCT06413342牵头方II期2024-06 启动
  2. Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)正在招募NCT06509568牵头方II期2024-08 启动
  3. Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy正在招募NCT06272214牵头方II期2024-03 启动
  4. A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC正在招募NCT06190639牵头方II期2023-10 启动
  5. Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC正在招募NCT05507411牵头方II期2022-08 启动
  6. Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma状态不明NCT06422858牵头方II期2024-05 启动
  7. Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer状态不明NCT05322499牵头方II期2022-04 启动
  8. Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma状态不明NCT04506138牵头方I/II期2020-08 启动
  9. A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.已暂停NCT04084158牵头方II期2019-09 启动
  10. A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer状态不明NCT03940001牵头方早期I期2019-05 启动
  11. Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma已完成NCT03381651牵头方不分期2018-02 启动
  12. S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer已完成NCT02813967牵头方III期2016-06 启动
  13. A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma状态不明NCT02570893牵头方III期2015-05 启动
  14. Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma状态不明NCT01688700牵头方II期2012-09 启动
  15. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients已完成NCT01258192牵头方II期2011-01 启动
  16. Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma邀请入组NCT06303583牵头方(推断)I/II期2022-06 启动
  17. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)正在招募NCT07405151研究中心I/II期2026-03 启动
  18. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  19. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC正在招募NCT06637163研究中心II期2024-10 启动
  20. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)正在招募NCT05319730研究中心I/II期2023-05 启动
  21. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  22. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  23. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  24. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  25. A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors进行中,不再招募NCT04603287研究中心I期2020-04 启动
  26. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  27. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  28. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  29. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  30. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  31. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  32. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186研究中心III期2015-03 启动
  33. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
  34. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)33
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncology论文
  3. 425eP Neoadjuvant chemoradiotherapy (nCRT) followed by sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Updated results of a single-arm, open-label phase Ib trial (CRIS)2025Annals of Oncology论文
  4. 464eP Phase II trial of adjuvant sintilimab in lymph node-positive esophageal squamous cell carcinoma (ESCC) after radical surgery without neoadjuvant treatment2025Annals of Oncology论文
  5. 655 Histopathologic Image–based Deep Learning Model for Predicting the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma2025Laboratory Investigation论文
  6. Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005).2025Journal of Clinical Oncology会议摘要
  7. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  8. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncology论文
  9. 1431P Assessing pathological complete response to neoadjuvant chemotherapy combined with immunotherapy in esophageal squamous cell carcinoma: A deep learning approach with voxel-level radiomics2024Annals of Oncology论文
  10. 406P Neoadjuvant chemo-immunotherapy versus neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma2024Annals of Oncology论文
  11. Abstract LB083: Near-infrared light-triggered tumor pyroptosis potentiates PD-1 immunotherapy in esophageal cancer2024Cancer Research会议摘要
  12. Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).2024Journal of Clinical Oncology会议摘要
  13. Comparing toripalimab combined with chemoradiotherapy versus chemoradiotherapy alone for locally advanced esophageal squamous cell carcinoma: A multicenter, open-label, randomized phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  14. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  15. High versus standard radiation dose of definitive chemoradiotherapy combined with immunotherapy for inoperable esophageal squamous cell carcinoma: A multicenter propensity score matching analysis.2024Journal of Clinical Oncology会议摘要
  16. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Square预印本
  17. Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS).2024Journal of Clinical Oncology会议摘要
  18. OA18.05 Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial2024Journal of Thoracic Oncology会议摘要
  19. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncology会议摘要
  20. Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two phase 2 clinical trials.2024Journal of Clinical Oncology会议摘要
  21. 2348P High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma2023Annals of Oncology论文
  22. A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).2023Journal of Clinical Oncology会议摘要
  23. Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma: A Randomized Phase II Clinical Trial2023International Journal of Radiation Oncology*Biology*Physics论文
  24. Metabolomics and transcriptomics joint analysis reveals altered amino acid metabolism in esophageal squamous cell carcinoma2023Research Square预印本
  25. Radiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Combined with Chemotherapy2023International Journal of Radiation Oncology*Biology*Physics论文
  26. A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.2022Journal of Clinical Oncology会议摘要
  27. Abstract 6054: Genomic and transcriptomic remodeling of esophageal squamous cell carcinoma by neo-adjuvant radiochemotherapy2022Cancer Research会议摘要
  28. EP07.02-006 Tumor Immune Microenvironment Related Makers are Overexpressed and Served as Favourable Prognostic Factors in Resectable ESCC2022Journal of Thoracic Oncology会议摘要
  29. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  30. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  31. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  32. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  33. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.2%。

牵头论文
35
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 8820232024: 8820242025: 12122025

杭州有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
    分期
    I/II期
    开始
    2025-03
    登记号
    NCT06741020

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  2. 正在招募
    Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
    分期
    II期
    开始
    2023-07
    登记号
    NCT05920863

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  3. 即将招募
    Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
    分期
    II期
    开始
    2027-09
    登记号
    NCT07691645

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  4. 正在招募
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-11
    登记号
    NCT07209813

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南京、南昌、杭州、郑州、长沙

  5. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  6. 正在招募
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2025-08
    登记号
    NCT07391839

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、南京、合肥、广州、杭州、济南、福州、郑州

  7. 正在招募
    Phase 2 Study of WGI-0301 for Advanced HCC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06309485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙

  8. 正在招募
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    分期
    III期
    开始
    2024-08
    登记号
    NCT06371157

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南京、杭州、郑州、长沙

  9. 即将招募
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07100236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、广州、杭州、温州、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后局部治疗(消融、TACE、HAIC)影像、人工智能与早期发现
论文中的科室肿瘤内科影像/核医学科普外/肝胆胰外科病理/检验科
牵头的论文35
  1. Heat stress-induced heat shock protein 90 alpha family class A member 1 upregulation stabilizes yes-associated protein through ubiquitination inhibition to boost hepatic cancer radiofrequency hyperthermia resistance.2026Cell stress & chaperones免费全文
  2. Comparison of the effective dose of alfentanil for percutaneous thermal ablation in subcapsular versus non-subcapsular hepatocellular carcinoma: a prospective dose-finding study utilizing the up-and-down sequential allocation method.2025BMC anesthesiology免费全文
  3. Integrating network pharmacology and transcriptomics to reveal the anti-hepatocellular carcinoma effects of Nigella B via activation of the P38MAPK pathway.2025Biochemical and biophysical research communications
  4. Integrating cell-free DNA methylation of SEPT9 and SFRP2 into a machine learning model for early diagnosis of HCC.2025Biomarkers in medicine免费全文
  5. Discovery and characterization of sulfonamide derivatives as transcriptional enhanced associate domain (TEAD) inhibitors: a novel approach for targeting hepatocellular carcinoma.2025Bioorganic chemistry
  6. A comparative study of DEB-TACE alone and DEB-TACE combined with targeted therapy and immunotherapy in the treatment of intermediate-advanced hepatocellular carcinoma.2025Cancer treatment and research communications
  7. Identification and validation a novel kinase-related gene signature for predicting prognosis and responsiveness to immunotherapy in hepatocellular carcinoma.2025Clinical and experimental medicine免费全文
  8. Inhibition of CYP1B1 by miR-200b-3p increases the sensitivity of paclitaxel in hepatocellular carcinoma treatment.2025Journal of pharmacological sciences
  9. DLAT activates EMT to promote HCC metastasis by regulating GLUT1-mediated aerobic glycolysis.2025Molecular medicine (Cambridge, Mass.)免费全文
  10. Transferrin promotes fatty acid oxidation and liver tumor growth through PHD2-mediated PPARα hydroxylation in an iron-dependent manner.2025Proceedings of the National Academy of Sciences of the United States of America免费全文
  11. Prediction of recurrence after resection in hepatocellular carcinoma via whole liver deep learning on preoperative contrast-enhanced CT.2025Scientific reports免费全文
  12. Identification and validation of PANoptosis-related LncRNAs prognosis system in hepatocellular carcinoma.2025Scientific reports免费全文
  13. Aptamer-Signatured Nanoparticle Protein Corona for Size-Dependent Fluorescent Barcoding Diagnosis.2025Small (Weinheim an der Bergstrasse, Germany)
  14. Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.2024Abdominal radiology (New York)
  15. Combined image-guided radiofrequency and iodine-125 seeds implantation in the treatment of recurrent hepatocellular carcinoma after hepatectomy.2024BMC cancer免费全文
  16. N6-methyladenosine regulators in hepatocellular carcinoma: investigating the precise definition and clinical applications of biomarkers.2024Biology direct免费全文
  17. A clinical-radiomic-pathomic model for prognosis prediction in patients with hepatocellular carcinoma after radical resection.2024Cancer medicine免费全文
  18. Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  19. A novel molecular classification system based on the molecular feature score identifies patients sensitive to immune therapy and target therapy.2024Frontiers in immunology免费全文
  20. Integrated Single-cell and Transcriptome Sequencing Analyses Identified PREX1 as an Immune-related Prognostic Biomarker for Liver Hepatocellular Carcinoma.2024International journal of medical sciences免费全文
  21. DNMT3L inhibits hepatocellular carcinoma progression through DNA methylation of CDO1: insights from big data to basic research.2024Journal of translational medicine免费全文
  22. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.2023BMC cancer免费全文
  23. In vitro comparative study of multimodal imaging nano-assembled microspheres with two clinical drug-eluting beads loaded with doxorubicin.2023Drug delivery免费全文
  24. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.2023Frontiers in immunology免费全文
  25. Risk factors for posttransplant diabetes in patients with hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  26. Radiomics-guided prognostic assessment of early-stage hepatocellular carcinoma recurrence post-radical resection.2023Journal of cancer research and clinical oncology免费全文
  27. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.2023Journal of clinical laboratory analysis免费全文
  28. Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE.2023Medicine免费全文
  29. Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signaling.2023Molecular genetics and genomics : MGG免费全文
  30. CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells.2022Disease markers免费全文
  31. Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma.2022Frontiers in public health免费全文
  32. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.2021Bioengineered免费全文
  33. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  34. Hepatoid Adenocarcinoma of the Lung.2021Technology in cancer research & treatment免费全文
  35. Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)39
  1. Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma正在招募NCT06741020牵头方I/II期2025-03 启动
  2. Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors正在招募NCT05920863牵头方II期2023-07 启动
  3. A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.状态不明NCT06349044牵头方不分期2024-03 启动
  4. Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC状态不明NCT05007587牵头方早期I期2021-07 启动
  5. Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma状态不明NCT05971199牵头方II期2021-11 启动
  6. Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma状态不明NCT05053386牵头方不分期2021-10 启动
  7. Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor已完成NCT05502458牵头方II期2020-12 启动
  8. TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients状态不明NCT04066543牵头方II期2019-08 启动
  9. Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome即将招募NCT07691645牵头方(推断)II期2027-09 启动
  10. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07209813研究中心II期2025-11 启动
  11. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.正在招募NCT07391839研究中心I期2025-08 启动
  12. 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness即将招募NCT07100236研究中心2025-08 启动
  13. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  14. Phase 2 Study of WGI-0301 for Advanced HCC正在招募NCT06309485研究中心II期2024-07 启动
  15. A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma正在招募NCT06371157研究中心III期2024-08 启动
  16. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  17. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma已完成NCT06310590研究中心I期2023-08 启动
  18. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma已完成NCT05864105研究中心II期2022-04 启动
  19. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  20. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  21. Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC状态不明NCT04920214研究中心2021-01 启动
  22. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  23. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  24. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  25. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  26. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  27. A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors进行中,不再招募NCT06239155研究中心I/II期2019-09 启动
  28. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  29. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  30. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  31. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  32. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  33. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  34. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  35. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  36. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  37. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma已完成NCT03113955研究中心不分期2017-10 启动
  38. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  39. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 106 篇,占 1.1%。

牵头论文
106
2021–2025 年
牵头试验
36
任何状态,ClinicalTrials.gov
牵头的开放试验
11
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 8820222023: 242420232024: 323220242025: 31312025

杭州有 9 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 22

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
    分期
    未注明
    开始
    2026-07
    登记号
    NCT07855640

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  2. 正在招募
    QL1706 Combined With SOX Used in Theperioperative Treatment
    分期
    I/II期
    开始
    2025-03
    登记号
    NCT06766305

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  3. 正在招募
    Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
    分期
    未注明
    开始
    2025-05
    登记号
    NCT07067983

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  4. 正在招募
    Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
    分期
    II期
    开始
    2025-11
    登记号
    NCT07325630

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  5. 正在招募
    Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06572319

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  6. 正在招募
    Study of IBI363 in Patients with Advanced First-line Gastric Cancer
    分期
    I期
    开始
    2024-10
    登记号
    NCT06610799

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  7. 正在招募
    Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06650332

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  8. 正在招募
    Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms
    分期
    未注明
    开始
    2021-06
    登记号
    NCT06078930

    年龄 18 岁 至 90 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  9. 即将招募
    A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
    分期
    II期
    开始
    2026-09
    登记号
    NCT07784413

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江省肿瘤医院杭州

  10. 即将招募
    Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
    分期
    III期
    开始
    2025-07
    登记号
    NCT07068516

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  11. 即将招募
    Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
    分期
    II期
    开始
    2024-04
    登记号
    NCT06374901

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省肿瘤医院杭州

  12. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南宁、大连、成都、杭州、武汉、石家庄、福州、苏州、银川

  13. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  14. 正在招募
    COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
    分期
    不分期
    开始
    2025-04
    登记号
    NCT06796764

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心杭州

  15. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  16. 正在招募
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    分期
    I期
    开始
    2025-02
    登记号
    NCT06873659

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、兰州、北京、南京、广州、杭州、济南、西安

  17. 正在招募
    Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
    分期
    II期
    开始
    2025-06
    登记号
    NCT06947291

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

  18. 正在招募
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    分期
    III期
    开始
    2025-06
    登记号
    NCT07029269

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心兰州、广州、杭州、福州、西安

  19. 正在招募
    A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
    分期
    II期
    开始
    2025-08
    登记号
    NCT07110571

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心杭州、石家庄

  20. 正在招募
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    分期
    I/II期
    开始
    2025-12
    登记号
    NCT07371663

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州、郑州

  21. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  22. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    分期
    I期
    开始
    2022-02
    登记号
    NCT05262491

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、成都、杭州、济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期手术影像与人工智能
论文中的科室消化/肝病科病理/检验科影像/核医学科肿瘤内科
牵头的论文106
  1. Gastric neuroendocrine neoplasms: updated epidemiology and externally validated prognostic nomogram.2026International journal of surgery (London, England)
  2. Dual-Targeted Biomimetic Nanoparticles for Enhanced Delivery of Polyphyllin B Synergistically Induce Ferroptosis and Immunogenic Cell Death in Gastric Cancer.2025ACS applied materials & interfaces免费全文
  3. Skullcapflavone II Inhibits SLC1A4-Mediated L-Serine Uptake and Promotes Mitochondrial Damage in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. APOL2 Stabilizes Ku80 to Confer NHEJ-Mediated Radioresistance in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Development and validation of CT-based fusion model for preoperative prediction of invasion and lymph node metastasis in adenocarcinoma of esophagogastric junction.2025BMC medical imaging免费全文
  6. Long-term exposure to ambient air pollution and sequential carcinogenesis in the cardia gastric: a cross-sectional study.2025BMC medicine免费全文
  7. Advances and applications of multiomics technologies in precision diagnosis and treatment for gastric cancer.2025Biochimica et biophysica acta. Reviews on cancer
  8. Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.2025Cancer immunology, immunotherapy : CII免费全文
  9. Comprehensive analysis and experimental validation of disulfidptosis-associated prognostic signature and immune microenvironment characterization of gastric cancer.2025Cancer immunology, immunotherapy : CII免费全文
  10. Molecular and immune determinants of response in locally advanced deficient DNA mismatch repair/microsatellite instability-high gastric or gastroesophageal junction adenocarcinoma treated with neoadjuvant chemoimmunotherapy.2025Cell communication and signaling : CCS免费全文
  11. SMOC2 promotes peritoneal metastasis of gastric cancer involving Wnt/β-catenin pathway modulation and inducing angiogenesis.2025Clinical and experimental medicine免费全文
  12. The persistent risk of secondary malignancies in gastric neuroendocrine tumor survivors: a population-based analysis.2025Clinical and experimental medicine免费全文
  13. Combined Predictive Value of GLIM-Defined Malnutrition and Preoperative Adipose Tissue 18F-FDG Uptake for Recurrence-Free Survival After Radical Gastrectomy in Patients with Gastric Cancer.2025Current oncology (Toronto, Ont.)免费全文
  14. Metabolic signatures for gastric cancer diagnosis and mechanistic insights: a multicenter study.2025EMBO molecular medicine免费全文
  15. Influence of lymphadenectomy extent on the efficacy of immunotherapy in recurrent gastric cancer patients.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  16. Contour-like model for precision risk stratification in gastric cancer patients underwent neoadjuvant therapy: A multicenter retrospective study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. Clinicopathological features and survival differences between G/GEJ-CSC and GAC: A Propensity score-matched, large-scale cross-population retrospective study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Multiomics insights into BMI-related intratumoral microbiota in gastric cancer.2025Frontiers in cellular and infection microbiology免费全文
  19. Clinical-radiomic prognostic model integrating staging before and after neoadjuvant chemotherapy in gastric cancer: a multicenter retrospective study.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  20. Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody-drug conjugate development.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  21. UBE2D2 promotes gastric cancer progression by inhibiting ferroptosis through autophagy-dependent stabilization of CST1.2025International journal of biological macromolecules
  22. Adjuvant chemotherapy may have no significant survival benefit in older patients with stage II/III gastric cancer: a multicenter retrospective study.2025Journal of cancer research and clinical oncology免费全文
  23. Inhibition of integrin α3 suppresses gastric cancer progression via STAT3-mediated regulation of SLC1A5-dependent glutamine uptake.2025Journal of gastroenterology
  24. Prognosis and distant metastasis patterns of early-onset gastric cancer compared with late-onset: a large-scale, cross-population retrospective study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  25. AI-based large-scale screening of gastric cancer from noncontrast CT imaging.2025Nature medicine免费全文
  26. Machine learning-driven risk stratification for distant metastasis in gastric cancer: A comparative study of clinical features and composite indices integrated models.2025PloS one免费全文
  27. Inhibition of glutathione peroxidase 4 suppresses gastric cancer peritoneal metastasis via regulation of RCC2 homeostasis.2025Redox biology免费全文
  28. Decitabine promotes the differentiation of poorly differentiated gastric cancer cells and enhances the sensitivity of NK cell cytotoxicity via TNF-α.2025Scientific reports免费全文
  29. Development of a PANoptosis-related LncRNAs for prognosis predicting and immune infiltration characterization of gastric Cancer.2025Scientific reports免费全文
  30. GPX4 knockdown suppresses M2 macrophage polarization in gastric cancer by modulating kynurenine metabolism.2025Theranostics免费全文
  31. Evaluating log odds of positive lymph nodes as a prognostic tool in differentiated gastric cancer: A retrospective study.2025World journal of gastroenterology免费全文
  32. Identifying beneficial gastric cancer patient on prognosis after treating with perioperative or postoperative-only chemotherapy: a single-center real-world study.2025World journal of surgical oncology免费全文
  33. Prediction of HER2 Expression in Gastric Adenocarcinoma Based On Preoperative Noninvasive Multimodal 18F-FDG PET/CT Imaging.2024Academic radiology
  34. Blocking Ubiquitin-Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoA Desaturase.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  35. Clinicopathological features and prognostic significance of TAF1L in gastric cancer.2024BMC gastroenterology免费全文
  36. The role of reactive oxygen species in gastric cancer.2024Cancer biology & medicine免费全文
  37. Current status of early gastric cancer screening research.2024Cancer biology & medicine免费全文
  38. Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis.2024Cancer medicine免费全文
  39. Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  40. Genomic biology and therapeutic strategies of liver metastasis from gastric cancer.2024Critical reviews in oncology/hematology
  41. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.2024European journal of clinical pharmacology
  42. AMBRA1 drives gastric cancer progression through regulation of tumor plasticity.2024Frontiers in immunology免费全文
  43. Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response.2024Gastroenterology
  44. Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer.2024Genome medicine免费全文
  45. Targeting ferroptosis in gastric cancer: Strategies and opportunities.2024Immunological reviews
  46. F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects.2024International journal of medical sciences免费全文
  47. Current development of molecular classifications of gastric cancer based on omics (Review).2024International journal of oncology免费全文
  48. Development and validation of a deep learning model for predicting gastric cancer recurrence based on CT imaging: a multicenter study.2024International journal of surgery (London, England)免费全文
  49. Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study.2024International journal of surgery (London, England)免费全文
  50. Revolutionizing T3-4N0-2M0 gastric cancer staging with an innovative pathologic N classification system.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  51. A retrospective study: exploring the optimal patient population for adjuvant chemotherapy after D2 gastrectomy.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  52. Prognostic significance of serum tumor markers in various pathologic subtypes of gastric cancer.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  53. Burdens of stomach and esophageal cancer from 1990 to 2019 and projection to 2030 in China: Findings from the 2019 Global Burden of Disease Study.2024Journal of global health免费全文
  54. C3+ cancer-associated fibroblasts promote tumor growth and therapeutic resistance in gastric cancer via activation of the NF-κB signaling pathway.2024Journal of translational medicine免费全文
  55. In-depth metaproteomics analysis of tongue coating for gastric cancer: a multicenter diagnostic research study.2024Microbiome免费全文
  56. The estrogen response in fibroblasts promotes ovarian metastases of gastric cancer.2024Nature communications免费全文
  57. Mutation characteristics and molecular evolution of ovarian metastasis from gastric cancer and potential biomarkers for paclitaxel treatment.2024Nature communications免费全文
  58. Mechanisms of traditional Chinese medicine in the treatment and prevention of gastric cancer.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  59. Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study.2024Scientific reports免费全文
  60. A novel color-aided system for diagnosis of early gastric cancer using magnifying endoscopy with narrow-band imaging.2024Surgical endoscopy
  61. Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.2024The oncologistRCT免费全文
  62. Catheter-guided anvil insertion for circular stapler esophagojejunal anastomosis: a novel technique in laparoscopic total gastrectomy.2024Updates in surgery免费全文
  63. Prognostic impact and reasons for variability by tumor location in gastric cancer.2024World journal of gastroenterology免费全文
  64. Development and validation of nomogram for predicting early recurrence after radical gastrectomy of gastric cancer.2024World journal of surgical oncologyRCT免费全文
  65. Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.2023BMC cancer免费全文
  66. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.2023BMC gastroenterology免费全文
  67. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.2023Cancer cytopathology
  68. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.2023Cancer medicine免费全文
  69. Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: A propensity score matching analysis.2023Cancer medicine免费全文
  70. The Pink Zone Pattern (PP) sign: A novel simple marker for early gastric cancer.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  71. Long Noncoding RNA AP000695.2 as a Novel Prognostic Biomarker for Gastric Cancer.2023Discovery medicine
  72. The role of macrophages in gastric cancer.2023Frontiers in immunology免费全文
  73. PRKAA1 predicts prognosis and is associated with immune characteristics in gastric cancer.2023Functional & integrative genomics
  74. Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  75. SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  76. Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study.2023Gut免费全文
  77. Polyphyllin B Suppresses Gastric Tumor Growth by Modulating Iron Metabolism and Inducing Ferroptosis.2023International journal of biological sciences免费全文
  78. Deep learning radio-clinical signatures for predicting neoadjuvant chemotherapy response and prognosis from pretreatment CT images of locally advanced gastric cancer patients.2023International journal of surgery (London, England)免费全文
  79. Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study.2023Journal of cancer research and clinical oncologyRCT免费全文
  80. Comparison of Clinicopathological Features and Prognosis of Mucinous Gastric Carcinoma and other Gastric Cancers: A Retrospective Study of 4,417 Patients.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  81. Risk Stratification and Overall Survival Prediction in Advanced Gastric Cancer Patients Based on Whole-Volume MRI Radiomics.2023Journal of magnetic resonance imaging : JMRI
  82. Integration and viral oncogene expression of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma and gastric cancer.2023Journal of medical virology
  83. The percentages of signet-ring cells (SRCs) affects the prognosis after radical gastrectomy for advanced gastric cancer.2023Langenbeck's archives of surgery
  84. Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.2023Nature communications免费全文
  85. Glutathione peroxidase 2 knockdown suppresses gastric cancer progression and metastasis via regulation of kynurenine metabolism.2023Oncogene免费全文
  86. Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer.2023Pharmacological research
  87. Conversion therapy for stage IV gastric cancer.2023Science bulletin
  88. A nomogram for predicting lymph node metastasis in early gastric signet ring cell carcinoma.2023Scientific reports免费全文
  89. Preoperative chemotherapy combined with para-aortic lymph node dissection has clinical value in the treatment of gastric cancer with para-aortic lymph node metastases.2022BMC surgery免费全文
  90. S3I-201 derivative incorporating naphthoquinone unit as effective STAT3 inhibitors: Design, synthesis and anti-gastric cancer evaluation.2022Bioorganic & medicinal chemistry
  91. Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.2022Frontiers in endocrinology免费全文
  92. Correlation of the detection rate of upper GI cancer with artificial intelligence score: results from a multicenter trial (with video).2022Gastrointestinal endoscopy
  93. CDH1 germline mutations in a Chinese cohort with hereditary diffuse gastric cancer.2022Journal of cancer research and clinical oncology免费全文
  94. Discovery of benzochalcone derivative as a potential antigastric cancer agent targeting signal transducer and activator of transcription 3 (STAT3).2022Journal of enzyme inhibition and medicinal chemistry免费全文
  95. The Endoscopic Submucosal Dissection Surgery in the Whole-Course Antegrade Endoscopic Approach: A More Effective Treatment Strategy for the Siewert II/III Type Mucosal Lesions of Esophagogastric Junction.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  96. Nucleic acid aptamer controls mycoplasma infection for inhibiting the malignancy of esophageal squamous cell carcinoma.2022Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  97. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial2021BMC cancer免费全文
  98. SIRT6 silencing overcomes resistance to sorafenib by promoting ferroptosis in gastric cancer.2021Biochemical and biophysical research communications
  99. A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression.2021Clinical and translational gastroenterology免费全文
  100. Intelligent Algorithm-Based Magnetic Resonance Imaging in Radical Gastrectomy under Laparoscope.2021Contrast media & molecular imaging免费全文
  101. Intelligent detection endoscopic assistant: An artificial intelligence-based system for monitoring blind spots during esophagogastroduodenoscopy in real-time.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  102. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer.2021Journal of clinical laboratory analysis免费全文
  103. Immunological impact of chemotherapy on the tumor microenvironment in gastric cancer.2021Journal of surgical oncology
  104. p-MEK expression predicts prognosis of patients with adenocarcinoma of esophagogastric junction (AEG) and plays a role in anti-AEG efficacy of Huaier.2021Pharmacological research
  105. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.2021The oncologist免费全文
  106. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).2021Trials免费全文
中文论文(未计入)7
  1. [Primary myoepithelioma in stomach with FUS::KLF17 gene fusion: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Preliminary exploration of esophagogastrostomy with modified Toupet-like anastomosis (mToupet-like) anastomosis after proximal gastrectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Epidemiological characteristics of gastric cancer in China and worldwide].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Five-year survival analysis of gastric cancer from population-based cancer registration data in Zhejiang province, China].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Functional outcomes of 100 patients with adenocarcinoma of the esophagogastric junction undergoing Cheng's GIRAFFE(®) reconstruction after proximal gastrectomy].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Experience and thoughts on digestive tract reconstruction after radical resection of adenocarcinoma of the esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Effect of reducing-opioids consumption on postoperative delirium incidence in elderly patients after gastric cancer surgery].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)69
  1. A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis即将招募NCT07784413牵头方II期2026-09 启动
  2. Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites正在招募NCT07855640牵头方2026-07 启动
  3. Clinical Evaluation of GRAPE Model for Gastric Cancer Screening正在招募NCT07067983牵头方2025-05 启动
  4. Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer正在招募NCT07325630牵头方II期2025-11 启动
  5. Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients正在招募NCT06650332牵头方I/II期2024-07 启动
  6. Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens正在招募NCT06572319牵头方I/II期2024-09 启动
  7. Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms正在招募NCT06078930牵头方2021-06 启动
  8. Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites进行中,不再招募NCT07855757牵头方不分期2026-06 启动
  9. Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy状态不明NCT06419140牵头方II期2024-06 启动
  10. Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer状态不明NCT06437678牵头方II期2024-05 启动
  11. A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.状态不明NCT06349044牵头方不分期2024-03 启动
  12. Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites状态不明NCT06046963牵头方II期2023-03 启动
  13. A Multi-omics-based Metabolic Typing Study of Gastric Cancer状态不明NCT06134011牵头方2023-09 启动
  14. Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics状态不明NCT05985577牵头方2023-03 启动
  15. Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma状态不明NCT05528367牵头方II期2022-01 启动
  16. A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer状态不明NCT05385809牵头方2022-06 启动
  17. DLCS for Predicting Neoadjuvant Chemotherapy Response状态不明NCT05617469牵头方2022-07 启动
  18. HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis状态不明NCT04889768牵头方不分期2021-07 启动
  19. Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer状态不明NCT05991947牵头方2021-03 启动
  20. Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics状态不明NCT05269056牵头方2021-09 启动
  21. Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy状态不明NCT04657848牵头方不分期2020-06 启动
  22. Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer状态不明NCT04135781牵头方III期2020-03 启动
  23. Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study状态不明NCT04190745牵头方II期2019-11 启动
  24. Whether Opioids Are Factor That Induced POD?已完成NCT05596071牵头方不分期2016-06 启动
  25. Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer状态不明NCT03276156牵头方I期2016-02 启动
  26. HIPEC, Intravenous Chemotherapy and Surgery for the Treatment of Advanced GC With Peritoneal Metastasis状态不明NCT02549911牵头方II期2015-09 启动
  27. D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer状态不明NCT01836991牵头方II期2012-01 启动
  28. Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer状态不明NCT01558947牵头方II期2011-01 启动
  29. Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer状态不明NCT01756183牵头方II期2011-09 启动
  30. Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer即将招募NCT07068516牵头方(推断)III期2025-07 启动
  31. QL1706 Combined With SOX Used in Theperioperative Treatment正在招募NCT06766305牵头方(推断)I/II期2025-03 启动
  32. Study of IBI363 in Patients with Advanced First-line Gastric Cancer正在招募NCT06610799牵头方(推断)I期2024-10 启动
  33. Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.即将招募NCT06374901牵头方(推断)II期2024-04 启动
  34. Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.状态不明NCT06642857牵头方(推断)2024-03 启动
  35. Nivolumab Combined With SOX Used in the Perioperative Treatment状态不明NCT05739045牵头方(推断)II期2022-11 启动
  36. Propofol EC50 for Inducing Loss of Consciousness in General Combined Epidural Anesthesia已完成NCT05124704牵头方(推断)不分期2021-11 启动
  37. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  38. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  39. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors正在招募NCT06873659研究中心I期2025-02 启动
  40. COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial正在招募NCT06796764研究中心不分期2025-04 启动
  41. Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors正在招募NCT06947291研究中心II期2025-06 启动
  42. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer正在招募NCT07029269研究中心III期2025-06 启动
  43. A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer正在招募NCT07110571研究中心II期2025-08 启动
  44. An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors正在招募NCT07371663研究中心I/II期2025-12 启动
  45. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  46. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor正在招募NCT05262491研究中心I期2022-02 启动
  47. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  48. Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration状态不明NCT06396143研究中心2024-07 启动
  49. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  50. Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis状态不明NCT06363123研究中心2024-03 启动
  51. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  52. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  53. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  54. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  55. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  56. Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab已完成NCT04276493研究中心I/II期2020-03 启动
  57. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  58. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  59. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347研究中心II/III期2019-12 启动
  60. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  61. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  62. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  63. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  64. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  65. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  66. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839研究中心III期2017-04 启动
  67. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)已完成NCT03221426研究中心III期2017-10 启动
  68. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  69. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 2 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

杭州有 20 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    分期
    II期
    开始
    2023-06
    登记号
    NCT05830123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文2
  1. Copper-Induced Cuproptosis and Immunogenic Cell Death Synergize with Radiotherapy and PD-1 Blockade in Osteosarcoma.2025ACS applied materials & interfaces
  2. Functional Role of RBP in Osteosarcoma: Regulatory Mechanism and Clinical Therapy.2023Analytical cellular pathology (Amsterdam)
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas正在招募NCT05830123研究中心II期2023-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
中文论文(未计入)2
  1. [Performance of the Combined Model Based on Both Clinicopathological and CT Texture Features in Predicting Liver Metastasis of High-risk Gastrointestinal Stromal Tumors].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  2. [Advances in recurrence risk assessment of gastrointestinal stromal tumor].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
早期论文(2016–2020 年)1
  1. Do we need to conduct full-thickness closure after endoscopic full-thickness resection of gastric submucosal tumors?2020The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 8 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Construction and Validation of an Intelligent Ultrasound Diagnostic System for the Spectrum of Neuroblastoma in Children进行中,不再招募NCT07549425研究中心2026-01 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

杭州有 9 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题双抗与抗体药物干细胞移植复发与耐药

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

杭州有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

杭州有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题诊断与预后淋巴瘤及肿瘤相关噬血

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

杭州有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

杭州有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

杭州有 10 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 4 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

浙江省肿瘤医院

Zhejiang Cancer Hospital

杭州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Cancer Hospital of the University of Chinese Academy of Sciences; Zhejiang Province Cancer Hospital; Taizhou Campus of Zhejiang Cancer Hospital (Taizhou Cancer Hospital); Cancer Hospital (Zhejiang Cancer Hospital); Zhejiang Cancer hospital; Zhejiang Cancer HospitalHangzhouP.R. China; Academy of Sciences (Zhejiang Cancer Hospital); University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

提出更正下载数据